Products
We believe that our technology has the potential to impact people's lives. That's why we're thrilled to present our offerings that utilize this proprietary technology.
Diabetes
Gvoke® Pre-Filled Syringe
(glucagon injection)
For more information about Gvoke Pre-Filled Syringe:
Visit the website Read the Prescribing Information Read the Instructions for UseGvoke HypoPen®
(glucagon injection)
For more information about Gvoke HypoPen:
Read the Prescribing InformationINDICATION AND IMPORTANT SAFETY INFORMATION
GVOKE is indicated for the treatment of severe hypoglycemia in adult and pediatric patients with diabetes ages 2 years and above.
IMPORTANT SAFETY INFORMATION
Contraindications
GVOKE is contraindicated in patients with pheochromocytoma because of the risk of substantial increase in blood pressure, insulinoma because of the risk of hypoglycemia, and known hypersensitivity to glucagon or to any of the excipients in GVOKE. Allergic reactions have been reported with glucagon and include anaphylactic shock with breathing difficulties and hypotension.
Warnings and Precautions
GVOKE is contraindicated in patients with pheochromocytoma because glucagon may stimulate the release of catecholamines from the tumor. If the patient develops a dramatic increase in blood pressure and a previously undiagnosed pheochromocytoma is suspected, 5 to 10 mg of phentolamine mesylate, administered intravenously, has been shown to be effective in lowering blood pressure.
In patients with insulinoma, administration of glucagon may produce an initial increase in blood glucose; however, GVOKE administration may directly or indirectly (through an initial rise in blood glucose) stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. GVOKE is contraindicated in patients with insulinoma. If a patient develops symptoms of hypoglycemia after a dose of GVOKE, give glucose orally or intravenously.
Allergic reactions have been reported with glucagon. These include generalized rash, and in some cases, anaphylactic shock with breathing difficulties and hypotension. GVOKE is contraindicated in patients with a prior hypersensitivity reaction.
GVOKE is effective in treating hypoglycemia only if sufficient hepatic glycogen is present. Patients in states of starvation, with adrenal insufficiency or chronic hypoglycemia, may not have adequate levels of hepatic glycogen for GVOKE administration to be effective. Patients with these conditions should be treated with glucose.
Necrolytic migratory erythema (NME), a skin rash commonly associated with glucagonomas (glucagon-producing tumors) and characterized by scaly, pruritic erythematous plaques, bullae, and erosions, has been reported postmarketing following continuous glucagon infusion. NME lesions may affect the face, groin, perineum and legs or be more widespread. In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. Should NME occur, consider whether the benefits of continuous glucagon infusion outweigh the risks.
Adverse Reactions
Most common (>5%) adverse reactions associated with GVOKE are nausea, vomiting, injection site edema (raised 1 mm or greater), and hypoglycemia.
Drug Interactions
Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE. In patients taking indomethacin, GVOKE may lose its ability to raise blood glucose or may even produce hypoglycemia. GVOKE may increase the anticoagulant effect of warfarin.
Gvoke (glucagon injection) is not approved outside of the U.S. For more information, including how to access Gvoke, please contact Xeris Medical Team at 1-877-XERIS371-877-XERIS37 (1-877-937-4737).
Our medicines are approved in individual countries for speciļ¬c uses, and the information shown is governed by local regulations. Always talk to your healthcare provider for advice about medicines.
We are also dedicated to the safety of our community of patients. If you experience side effects while taking any medication, be sure to let your doctor, nurse, or pharmacist know and then report it to the FDA.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-10881-800-FDA-1088 (1-800-332-1088).

You have chosen a link to an external site.
By clicking "ok", a new window will open.
Do you wish to continue?
OK No Thanks!Not opening? Check to see you have pop-ups enabled or copy link below in a new window.

Xeris Biopharma is excited to announce approval for a new product, furthering our commitment to improving more patient's lives. Read More
Product Pipeline
Xeris has a robust pipeline of development programs to extend the current marketed products into important new indications and uses and bring new products forward using its proprietary formulation technology platforms.
Find out more
Approved Products
Gvoke® (glucagon injection)
Fact Sheet
Keveyis® (dichlorphenamide)
Fact Sheet
Recorlev® (levoketoconazole)
Fact Sheet